2/2
08:00 am
ird
Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026
Low
Report
Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026
1/28
08:04 am
ird
Opus Genetics (NASDAQ:IRD) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $7.00 price target on the stock.
Medium
Report
Opus Genetics (NASDAQ:IRD) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $7.00 price target on the stock.
1/27
07:00 am
ird
Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa
Low
Report
Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa
1/21
06:19 am
ird
Opus Genetics (NASDAQ:IRD) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
Medium
Report
Opus Genetics (NASDAQ:IRD) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
1/20
07:01 am
ird
Opus Genetics (NASDAQ:IRD) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.
Medium
Report
Opus Genetics (NASDAQ:IRD) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.
1/8
07:00 am
ird
Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts
Medium
Report
Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts
1/3
01:08 am
ird
Low
Report
12/20
03:10 pm
ird
The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside [Yahoo! Finance]
Low
Report
The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside [Yahoo! Finance]
12/16
04:01 pm
ird
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12/11
07:00 am
ird
Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference
Low
Report
Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference
12/9
09:03 pm
ird
Opus Genetics (NASDAQ:IRD) is now covered by analysts at B. Riley. They set a "buy" rating on the stock.
Medium
Report
Opus Genetics (NASDAQ:IRD) is now covered by analysts at B. Riley. They set a "buy" rating on the stock.
12/9
07:00 am
ird
Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease
Medium
Report
Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease
12/2
04:01 pm
ird
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12/2
06:16 am
ird
Opus Genetics (NASDAQ:IRD) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
Low
Report
Opus Genetics (NASDAQ:IRD) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
11/29
01:34 am
ird
Piper Sandler Initiates Coverage on Opus Genetics, Inc. (IRD) With “Overweight” Rating and $7 PT [Yahoo! Finance]
Medium
Report
Piper Sandler Initiates Coverage on Opus Genetics, Inc. (IRD) With “Overweight” Rating and $7 PT [Yahoo! Finance]
11/26
06:43 am
ird
Opus Genetics (NASDAQ:IRD) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
Low
Report
Opus Genetics (NASDAQ:IRD) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
11/25
06:11 am
ird
Opus Genetics (NASDAQ:IRD) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
Medium
Report
Opus Genetics (NASDAQ:IRD) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
11/20
08:36 am
ird
Opus Genetics to Participate in Upcoming Investment Conferences [Yahoo! Finance]
Low
Report
Opus Genetics to Participate in Upcoming Investment Conferences [Yahoo! Finance]
11/20
08:00 am
ird
Opus Genetics to Participate in Upcoming Investment Conferences
Medium
Report
Opus Genetics to Participate in Upcoming Investment Conferences
11/13
07:07 pm
ird
Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease [Yahoo! Finance]
Low
Report
Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease [Yahoo! Finance]
11/13
08:46 am
ird
Opus Genetics (NASDAQ:IRD) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $9.00 price target on the stock.
Medium
Report
Opus Genetics (NASDAQ:IRD) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $9.00 price target on the stock.
11/13
07:00 am
ird
Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease
Medium
Report
Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease
11/12
08:19 am
ird
Opus Genetics GAAP EPS of -$0.25 misses by $0.12, revenue of $3.08M in-line [Seeking Alpha]
Low
Report
Opus Genetics GAAP EPS of -$0.25 misses by $0.12, revenue of $3.08M in-line [Seeking Alpha]
11/12
07:00 am
ird
Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update
Low
Report
Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update
11/7
10:27 am
ird
Opus Genetics (NASDAQ:IRD) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $9.00 price target on the stock.
Medium
Report
Opus Genetics (NASDAQ:IRD) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $9.00 price target on the stock.